025 An Additional New Hope - Understanding GPRC5D Treatment

This episode introduces Talquetamab - a newly approved bispecific antibody for relapsed myeloma - explaining how it works, who it’s for, and what side effects patients should expect and prepare for.



📌Key Takeaways:




• Talquetamab is a brand-new treatment targeting GPRC5D - offering another effective option after several previous therapies.


• Early side effects like fever, blood pressure changes or confusion are monitored closely and are almost always reversible.


• Taste changes, mouth soreness, skin issues and nail changes are common - but they can usually be managed so patients can stay on the treatment.




For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/



This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns



 



ABOUT YOUR HOSTS



Dr. Jam Kothari



Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.



 



Dr. Sally Moore



Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.